“While we’ve made great progress in diagnosing rare genetic diseases for critically ill newborns and children, only an estimated 10% of childhood genetic diseases currently have effective treatments,” Stephen Kingsmore, president and CEO of the Rady Institute for Genomic Medicine, told Clinical Omics. “The collaboration with Takeda is our Institute’s first effort focused on ending the therapeutic odyssey for patients with rare disease.”
Menu